EN
登录

Rosemont Pharmaceuticals将收购 Aytu BioPharma,以加速在美国的扩张

Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion

GlobeNewswire 等信源发布 2026-11-16 21:11

可切换为仅中文


Agreement to acquire Aytu BioPharma for all-cash consideration of $2.70 per Aytu share.

同意以每股Aytu股票2.70美元的全现金对价收购Aytu BioPharma。

Proposed acquisition brings an established ADHD portfolio and an emerging Major Depressive Disorder (MDD) asset alongside a US commercial platform.

拟议的收购将带来成熟的注意缺陷多动障碍(ADHD)产品组合和新兴的重度抑郁症(MDD)资产,以及一个美国商业化平台。

Closing anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions in the tender offer.

预计交易将于2026年12月下旬完成,前提是满足或豁免要约收购中的相关条件。

GREENVILLE, S.C. and LEEDS, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), a global specialty pharmaceutical company focused on designing and delivering medicines around patients’ needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc.

南卡罗来纳州格林维尔和英国利兹,2026年11月16日(环球电讯社)——全球专业制药公司Rosemont Pharmaceuticals Holdings, Inc.(“Rosemont”),专注于围绕患者需求设计和提供药物,今日宣布已签订最终合并协议,以收购Aytu BioPharma, Inc.。

(“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases..

(“Aytu”)(纳斯达克股票代码:AYTU),一家专注于推进针对复杂中枢神经系统(CNS)疾病的创新药物的美国专业制药公司。

The proposed acquisition represents a significant step in Rosemont’s global growth strategy, building on its established US presence and strengthening its position in the specialty pharmaceutical market. By bringing together complementary portfolios, expertise and commercial capabilities including omnichannel and digital marketing expertise, Rosemont aims to accelerate growth, expand its reach and create new opportunities across international markets..

此次拟议收购是罗斯蒙特全球增长战略的重要一步,在其既有的美国市场基础上,进一步强化其在 specialty pharmaceutical(专科制药)市场的地位。通过整合互补的产品组合、专业知识以及包括全渠道和数字营销能力在内的商业优势,罗斯蒙特旨在加速增长,扩大市场覆盖范围,并在国际市场上创造新的机遇。

Rosemont Pharmaceuticals is backed by Inflexion, a leading European-headquartered mid-market private equity firm with investing offices in London, New York, Amsterdam, Frankfurt and Stockholm. Inflexion has $21bn of assets under management and a dedicated on-the-ground team in New York City which was established in 2025..

Rosemont Pharmaceuticals 由 Inflexion 支持。Inflexion 是一家总部位于欧洲的领先中端市场私募股权公司,在伦敦、纽约、阿姆斯特丹、法兰克福和斯德哥尔摩设有投资办公室。Inflexion 的管理资产规模为 210 亿美元,并于 2025 年在纽约市组建了一支专门的本地团队。

Alok Sonig, Chief Executive Officer of Rosemont Pharmaceuticals, said: “The proposed acquisition of Aytu marks an important step in Rosemont’s US growth strategy. Aytu has built an established CNS adult and paediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities.

Rosemont Pharmaceuticals 首席执行官 Alok Sonig 表示:“拟议收购 Aytu 是 Rosemont 美国增长战略的重要一步。Aytu 已建立起一家专注于中枢神经系统(CNS)成人及儿童领域的特色制药企业,拥有优秀人才、差异化产品组合以及经市场验证的商业化能力。”

Together with Rosemont’s product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth. We look forward to welcoming the Aytu team once the transaction is complete.”.

凭借Rosemont在产品开发、监管事务、生产制造及商业化方面的专业知识,我们相信能够构建一个强劲的未来增长平台。我们期待在交易完成后欢迎Aytu团队的加入。”

Josh Disbrow, Chief Executive Officer of Aytu BioPharma, said: “This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines.

Aytu BioPharma 首席执行官 Josh Disbrow 表示:“与 Rosemont 达成的这项协议,反映了我们团队在构建中枢神经系统和儿科产品组合方面所做的工作,以及我们赢得所服务的患者和医疗保健提供者信任的努力。我们认为,我们的产品组合与 Rosemont 在开发和商业化专科药物方面的经验之间具有强大的战略契合度。”

Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”.

重要的是,我们相信此次交易将为我们的股东带来可观的价值,并且通过携手合作,我们能够帮助更多患者获得他们所需的治疗。

Under the terms of the merger agreement, a wholly owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock at $2.70 per share in cash. The price represents a 41.1% premium to Aytu’s 30-day volume-weighted average share price. The transaction is structured as a tender offer to be followed by a merger, subject to customary conditions to the tender offer and merger, including the tender of shares representing at least a majority of the total number of outstanding shares of Aytu common stock and the exercise or termination of certain of Aytu’s outstanding warrants..

根据合并协议的条款,Rosemont 的一家全资子公司将启动要约收购,以每股 2.70 美元的现金价格收购 Aytu 所有流通在外的普通股。该价格较 Aytu 过去 30 个交易日的成交量加权平均股价溢价 41.1%。本次交易采用先进行要约收购、随后进行合并的结构,须满足要约收购及合并的常规条件,包括代表至少过半数 Aytu 流通在外普通股总数的股份被接受要约,以及 Aytu 某些流通在外认股权证的行权或终止。

Following the successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered in the tender offer (other than shares for which appraisal rights are properly exercised) through a second-step merger at the same price paid in the tender offer.

在要约收购成功完成后,Rosemont 将通过第二步合并,以与要约收购中相同的对价,收购所有未在要约收购中提交的要约股份(但依法行使评估权的股份除外)。

Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days, and Aytu will file a Schedule 14D-9 with respect to the tender offer substantially concurrently with the commencement of the tender offer, each of which will include additional details on the transaction and process undertaken by the Company..

Rosemont 计划在10个工作日内启动要约收购并提交Schedule TO文件,而Aytu将在要约收购启动的同时提交与此次要约收购相关的Schedule 14D-9文件,上述文件均将包含有关交易及公司所采取流程的更多详细信息。

The transaction was unanimously approved by the Aytu board of directors and closing is anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions to the tender offer. Aytu’s executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed tender and support agreements under which such stockholders agreed, among other things, to tender their shares in the tender offer and to the termination or exercise of any warrants held by them prior to the Effective Time, in exchange for the consideration payable in connection with the transaction in accordance with the terms of such warrants..

该交易已获得Aytu董事会的一致批准,预计将于2026年12月下旬完成交割,前提是满足或豁免要约收购的各项条件。Aytu的高级管理人员、董事以及与Nantahala Capital Management和Stonepine Capital Management有关联的某些股东已签署要约收购和支持协议,根据这些协议,这些股东同意(其中包括)在要约收购中提交其股份,并在生效时间之前终止或行使其持有的任何认股权证,以按照此类认股权证的条款换取与交易相关的对价。

Until the proposed acquisition completes, Rosemont and Aytu will remain separate companies and continue to operate independently. Following completion, a key priority will be ensuring a smooth transition, maintaining continuity of supply and service for customers and partners, and keeping the needs of patients and healthcare professionals at the heart of everything we do..

在拟议的收购完成之前,Rosemont 和 Aytu 将保持为独立的公司,并继续独立运营。收购完成后,首要任务将是确保平稳过渡,维持对客户和合作伙伴的供应与服务连续性,并将患者及医疗健康专业人士的需求置于我们所有工作的核心位置。

Bourne Partners is acting as financial adviser to Rosemont, and Ropes & Gray LLP is serving as Rosemont’s legal counsel. Canaccord Genuity is acting as financial adviser to Aytu BioPharma and Dorsey & Whitney LLP is serving as its legal counsel.

伯恩合伙公司担任罗斯蒙特的财务顾问,罗普斯与格雷律师事务所担任罗斯蒙特的法律顾问。Canaccord Genuity 担任 Aytu BioPharma 的财务顾问,多西·惠特尼律师事务所担任其法律顾问。

CONTACTS

联系人

Global Media Enquiries

全球媒体咨询

Jack Faulkner, Internal & External Communications Manager, Rosemont Pharmaceuticals:

杰克·福克纳,罗丝蒙特制药公司内外部沟通经理:

jack.faulkner@rosemontpharma.com

jack.faulkner@rosemontpharma.com

US Media Enquiries

美国媒体咨询

Michael Fitzhugh, VP, Chief of Media Strategy, Life Sci Communications:

Michael Fitzhugh,副总裁兼媒体战略主管,Life Sci Communications

mfitzhugh@lifescicomms.com

mfitzhugh@lifescicomms.com

NOTES TO EDITORS

编者注

About Rosemont Pharmaceuticals

关于罗斯蒙特制药

Rosemont Pharmaceuticals is a global pharmaceutical company specializing in the development, manufacture and supply of oral liquid medicines. For nearly 60 years, Rosemont has focused on creating alternative dosage forms that help address the needs of patients who may have difficulty swallowing solid oral medicines..

Rosemont Pharmaceuticals 是一家全球性制药公司,专注于口服液体制剂的开发、生产和供应。近60年来,Rosemont 一直致力于开发替代剂型,以满足吞咽固体口服药物存在困难的患者需求。

Through its broad portfolio across multiple therapeutic areas, Rosemont works to support patients, caregivers and healthcare professionals by improving access to medicines in formulations designed to meet diverse patient needs. Rosemont Pharmaceuticals is headquartered in Leeds in the United Kingdom and serves patients across international markets through a growing portfolio of licensed medicines..

Rosemont 凭借其在多个治疗领域的广泛产品组合,致力于通过提供为满足多样化患者需求而设计的剂型,改善药品可及性,从而支持患者、照护者和医疗保健专业人员。Rosemont Pharmaceuticals 总部位于英国利兹,通过不断增长的许可药品产品组合,为国际市场的患者提供服务。

For more information, please visit:

更多信息,请访问:

www.rosemontpharma.com

www.rosemontpharma.com

About Aytu BioPharma

关于 Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company’s prescription products include EXXUA

Aytu 是一家制药公司,专注于推进针对复杂中枢神经系统疾病的创新药物,以改善患者的生活质量。公司的处方产品包括 EXXUA

®

®

(gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention-deficit/hyperactivity disorder (ADHD).

(吉哌隆)缓释片(详见完整处方信息,包括黑框警告),用于治疗重度抑郁障碍(MDD),以及注意缺陷/多动障碍(ADHD)的治疗。

Aytu is committed to delivering the Company’s medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit

Aytu 致力于通过行业领先的患者援助计划提供公司药物,以帮助实现最佳的患者治疗结果。欲了解更多信息,请访问

aytubio.com

aytubio.com

or follow us on LinkedIn.

或在 LinkedIn 上关注我们。

About Inflexion

关于 Inflexion

Inflexion is a leading European mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth. Inflexion's flexible approach allows it to back both majority and minority investments, typically backing companies with an enterprise valuation ranging from €50m to €1 billion..

Inflexion 是一家领先的欧洲中型市场私募股权公司,与高增长、创业型企业的雄心勃勃的管理团队合作,加速其可持续增长。Inflexion 采用灵活的投资策略,既进行多数股权投资,也进行少数股权投资,通常支持企业估值在 5000 万欧元至 10 亿欧元之间的公司。

With bespoke teams and dedicated capital, Inflexion's funds invest across a variety of sectors from offices in London, Manchester, Amsterdam, Stockholm, Frankfurt and New York. Inflexion helps businesses achieve the next stage of growth through M&A, international expansion, digital enhancement, talent development, commercial strategy, sustainability focus and access to Inflexion's global network..

凭借定制化团队和专项资本,Inflexion 的基金从伦敦、曼彻斯特、阿姆斯特丹、斯德哥尔摩、法兰克福和纽约的办公室出发,投资于多个行业。Inflexion 通过并购、国际扩张、数字化转型、人才发展、商业战略、可持续发展聚焦以及接入 Inflexion 全球网络,帮助企业实现下一阶段的成长。

Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.€16bn.

由Inflexion Private Equity Partners LLP管理的基金,其管理资产规模约为160亿欧元。

Read more at

了解更多,请访问

www.inflexion.com

www.inflexion.com

Forward-Looking Statements

前瞻性陈述

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release are forward-looking statements.

本新闻稿包含经修订的《1933年证券法》(“《证券法》”)第27A条和经修订的《1934年证券交易法》(“《交易法》”)第21E条所定义的前瞻性陈述。除本新闻稿中包含的历史事实陈述外,所有陈述均为前瞻性陈述。

Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology.

前瞻性陈述通常使用将来时态书写,和/或以“可能”、“将”、“应当”、“预测”、“能够”、“预期”、“建议”、“相信”、“估计”、“继续”、“预料”、“打算”、“计划”等词语或其否定形式、其他变体或类似术语作为前缀。

These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many Aytu stockholders will tender their shares in the tender offer; the possibility that the conditions to the tender offer and the merger may not be satisfied or waived; the occurrence of any event that could give rise to the termination of the merger agreement; the effects of the transaction on relationships with employees, customers, suppliers and other business partners; potential stockholder litigation or regulatory action relating to the transaction; the Company’s overall financial and operational performance, potential adverse changes to the Company’s financial position or its business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining mar.

上述陈述属于预测性陈述,受各种风险和不确定因素的影响,可能导致实际事件或结果与预测存在重大差异。这些风险和不确定性包括但不限于与以下方面相关的风险:要约收购及合并的时间安排存在不确定性;参与要约收购并交出其股份的Aytu股东人数存在不确定性;要约收购和合并的先决条件可能无法满足或被豁免的可能性;任何可能导致合并协议终止的事件的发生;本次交易对员工、客户、供应商及其他业务合作伙伴关系的影响;与本次交易相关的潜在股东诉讼或监管行动;公司的整体财务和经营业绩、公司财务状况或业务可能出现的重大不利变化、经营成果、战略和计划、资本市场的变化以及公司按预期方式为其运营融资的能力,以及与获得市场相关的风险。

Additional Information and Where to Find It

附加信息及查询途径

The tender offer for all of the outstanding shares of Aytu described in this communication has not yet commenced. This press release is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Rosemont and its acquisition subsidiary will file with the SEC upon commencement of the tender offer.

本通讯中所述的针对Aytu所有流通股的要约收购尚未开始。本新闻稿仅提供信息,不构成任何建议,既不是购买任何证券的要约,也不是出售任何证券的要约邀请,亦不能替代Rosemont及其收购子公司在要约收购启动时向美国证券交易委员会(SEC)提交的要约收购文件。

A solicitation and offer to buy outstanding shares of Aytu will only be made pursuant to the tender offer materials that Rosemont and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Rosemont and its acquisition subsidiary will file tender offer materials on Schedule TO, and Aytu will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.

收购Aytu已发行股份的要约邀请及购买要约,将仅依据Rosemont及其收购子公司拟向美国证券交易委员会(SEC)提交的要约收购文件进行。在要约收购启动时,Rosemont及其收购子公司将提交附表TO项下的要约收购文件,而Aytu将就此次要约收购向SEC提交附表14D-9项下的征求/推荐声明。

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF AYTU ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF AYTU SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER.

要约收购材料(包括购买要约、相关的递交函以及某些其他要约收购文件)和征求/推荐声明将包含有关拟议收购及其各方的重要信息。敦促 AYTU 的投资者和股东在这些文件发布时仔细阅读(并随时关注其可能作出的修订或补充),因为这些文件将包含重要信息,AYTU 的投资者和股东在就其在要约收购中是否递交普通股股份作出任何决定之前应予以考虑。

The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Aytu at no expense to them on the SEC’s website at .

要约收购材料(包括购买要约及相关的递交函)以及征求/推荐声明,将在美国证券交易委员会(SEC)网站上向Aytu的所有股东免费提供。

www.sec.gov

www.sec.gov

and (once they become available) will be mailed to the stockholders of Aytu free of charge. Additional copies may be obtained for free by contacting Aytu, or by contacting Sodali & Co, the information agent for the Offer, toll-free at (800) 662-5200 or at

并将在备妥后免费邮寄给 Aytu 的股东。如需额外副本,可免费联系 Aytu,或联系本次要约的信息代理 Sodali & Co,拨打免费电话 (800) 662-5200 或通过

AYTU.info@investor.sodali.com

AYTU.info@investor.sodali.com

The information contained in, or that can be accessed through, the SEC’s website is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Aytu files annual, quarterly, and current reports, proxy statements and other information with the SEC.

美国证券交易委员会(SEC)网站上包含或可通过其访问的信息不构成本文的一部分,也不通过引用方式纳入本文。除收购要约、相关的递交函及某些其他要约收购文件,以及征求/推荐声明外,Aytu 还向美国证券交易委员会提交年度报告、季度报告、当前报告、委托书声明及其他信息。

You may read any reports, statements or other information filed by Aytu with the SEC for free on the SEC’s website at .

您可以免费在美国证券交易委员会(SEC)网站 上查阅 Aytu 向 SEC 提交的任何报告、声明或其他信息。

www.sec.gov

www.sec.gov

.

。